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Definition
• Myocardial bridge  is  defined  as  a  segment  of   the  
major  coronary  artery  running  intramurally through  
the  myocardium,  deviating  from  its  usual  epicardial
course.
• Synonyms: (intramural coronary artery, mural coronary artery, coronary 
overbridging, myocardial loop)
• First described anatomically by Reyman in 1737
Etiology
• congenital anomaly of the coronary arteries
• rates much higher than the general population in the 
following conditions:
– hypertrophic cardiomyopathy patients 
– heart transplant patients:  related to the increased stiffness and 
hypertrophy of the myocardium post transplant, resulting in 
increased rates of systolic vessel compression
• Schematic Diagram of the Effects of Aging 
on the Myocardial Bridge (A) Heart with 
myocardial bridging, early 
stage. (B) Longitudinal view of the bridged 
vessel. (C) Cross-sectional view of the 
vessel in the middle of the myocardial 
bridge. (A′) Heart with myocardial bridging, 
late stage, with ventricular hypertrophy and 
diastolic dysfunction. (B′) Longitudinal view 
of the bridged vessel, with hypertrophied 
muscle and plaque progression proximal to 
the bridge. (C′) Cross-sectional view of the 
vessel in the middle of the myocardial 
bridge showing hypertrophied muscle and 
negative remodeling of the vessel with 
decreased lumen diameter.
Pathogenesis
• The myocardial bridge causes coronary artery narrowing 
during systole therefore myocardial bridges should not 
compromise blood supply to the musculature during 
diastole. 
• Systolic narrowing at the myocardial bridging segment 
may result in endothelial damage, which may provoke 
platelet aggregation, coronary vasospasm and eventually 
acute coronary syndrome
Pathogenesis
– the vessel segment proximal to the bridge appears to develop 
atherosclerosis at increased rates, approaching 90% rather 
than the myocardial bridging segment itself . Research has 
shown vasoactive agents (endothelin-1, endothelial nitric oxide 
synthase and angiotensin-converting enzyme) to be present in 
higher concentrations in the proximal portion of the myocardial 
bridging artery compared to the myocardial bridging segment. It 
can also be an alternative cause of ischemia in patients with 
myocardial bridging.
Pathogenesis
• Bridging is typically described for left anterior descending 
artery (LAD), with the mid LAD considered the most 
common location , however, other major coronary arteries 
can also be involved 
Clinical Manifestations (Features)
• Symptomatic patients with myocardial bridging may present with 
• myocardial ischemia, 
• acute coronary syndromes, 
• coronary spasm, 
• exercise-induced dysrhythmias (such as supraventricular tachycardia, ventricular 
tachycardia, or atrioventricular block), 
• myocardial stunning, 
• transient ventricular dysfunction, 
• syncope,
• sudden death. 
When myocardial bridging is associated with heart valve disorder or cardiomyopathies, the 
patients' symptoms can be different. 
Diagnosis
• Coronary angiography: The typical angiographic feature of a 
myocardial bridge is systolic narrowing of an epicardial artery, 
which is often completely resolved during the diastolic phase of 
the cardiac cycle.
• Intracoronary Doppler
• Echocardiography
• Electrocardiography
• Stress test with ECG
• Intravascular ultrasound
• Fractional flow reserve
• Cardiac computed tomography (CT) angiography
Prognosis
• Myocardial bridging is generally considered to be a benign condition, it has 
been proposed as a cause of angina-like chest pain, coronary spasm, 
myocardial ischemia, acute coronary syndromes, left ventricular 
dysfunction/stunning, arrhythmias (including supraventricular tachycardia 
and ventricular tachycardia), and even sudden cardiac death. Serious 
events are uncommon, and it is still controversial and unclear whether 
myocardial bridging can be directly attributed as the cause of the events
Management
• Pharmacologic therapy:
First-line therapy: beta-blockers and non-dihydropyridine
calcium-channel blockers (decreased chronotropy and 
inotropy i.e prolongation of diastole with reductions in 
heart rate)
–Nitrates are contraindicated in patients 
• Surgical treatment: surgical myotomy and coronary 
stenting
Patient Identifying data
• Age: 67 years old
• Sex: Female
Complaints
Main complaints:
• retrosternal pressing  pain that occurs either after 
emotional stress or without clear connection with any 
provoking factors,  relieves in rest 
• Unstable blood pressure 
• Review of other organs and systems reveals no complaints
History of the present disease
– She has been suffering from hypertension since the last 20 years. Maximum BP level
(210/100 mmHg) was noticed 4 years ago when patient lost consciousness. The
ambulance was called. No significant changes on ECG were revealed. After those
incident she periodically hospitalized in CCH and received antihypertensive treatment
(ampril 2,5 mg , bisoprolol 5 mg, fisiotens 0,4 mg) «Working» BP 140/80 mmHg,
• Since last year she has been suffering from retrosternal pain that occurs either after 
emotional stress or without connection with any provoking factors,  relieves in rest without 
taking any medicines. The complaints on retrosternal pain brought patient to the hospital for 
examination and treatment
Life history
• No previous surgery
• No history of tuberculosis
Physical examination
• No   physical   abnormalities were detected by clinical   
examination  and  blood   pressure   was 140/80 mmHg 
(on the background of antihypertensive medication ) , HR 
61 bpm 
• Respiratory rate: no significant changes
• Auscultation: clear vesicular sound
• Accentuated second sound over the aorta
• Abdomen without any changes
• Obesity of 1st degree
Day-night BP monitoring
No Beginning HR Systolic BP Diastolic 
BP
1
2
4
12
16
22
26
27
28
32
33
34
37
38
39
40
42
11:28:00
11:59:34
12:33:45
15:51;09
17;00;41
19:43:39
21:22:16
21:53:52
22:25:32
23:33:07
00:33:48
01:35:25
03:38:52
04:40:30
05:41:52
06:43:20
08:17:09
68
77
66
64
60
70
76
62
51
70
57
49
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51
61
96
146
163
149
137
149
136
123
122
123
133
114
119
91
115
148
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141
78
89
70
78
81
59
52
59
57
69
51
58
44
60
69
76
70
• BP monitoring was 
done on the 
background of 
antihypertensive 
drugs
• Changes for BP is 
typical for mild 
hypertension
Preliminary diagnosis
• Arterial hypertension  stage II 3 degree. Hypertensive 
heart HF 0-1
• IHD.Stable angina
• Obesity 1 degree
Plan of investigation
• Minimum investigation:
– Complete blood count
– Urine analysis
– Blood analysis (glucose, creatinine, lipid profile, total bilirubin, 
АSТ, АLТ)
– ECG
– EchoCG
– Coronary arteriography 
– Exercise treadmill test
Lipid profile/Blood test
• triglycerides   3.3mmol/L( ≤ 2.3)  
• high   density   lipoprotein   cholesterol   1.43mmol/L( ≥ 
0.9),   total   cholesterol  7.93 mmol/L(<5.2),
• low   density   lipoprotein   cholesterol  0.77   
mmol/L(<3.5),
• blood glucose 5.5 mmol/L(3.5-5.5)
• Atherogenic coefficient 4.54(≤ 3)
All other blood tests also were normal
ECG
• Conclusion : Sinus rhythm. Signs of left ventricular 
hypertrophy
EchoCG
• Diameter of aorta 32mm(20-37mm)
• Mitral valve opening: 29mm(26-35mm)
• Left atrium: 32mm
• Left ventricle, end diastolic diameter: 40mm(35-55), end systolic diameter: 
25mm(23-38mm), ejection fraction: 65%(55-78%), systolic fraction 34%(28-
44%) 
• Interventricular septum: 11.8mm(6-11mm)
• Right atrium:28mm, Right ventricle: 18mm(9-26) 
• Thickness of LV posterior wall- 12.7 mm(6-11mm)
• Conclusion: there is atherosclerotic changes of the aorta, hypertrophy of the 
left ventricle
Exercise treadmill test
• While doing exercise treadmill test  (protocol Bruce):  blood pressure, heart 
rate and 12-leads ECG were recorded during several steps with increased 
physical exertions (from 4,6 METs). The ECG and  ST-segment   were 
continuously   displayed  and   measured automatically  by  a   computer-
assisted system in all 12 leads.
• Max reached BP was 180/100 mmHg, max HR 127 bpm. At heart rate of 127 
beat/minute (7,0METs), the ST segment showed progressive depression 
more then 1,0 mm in leads II, III, avf, V4,V5, V6 that necessitated termination 
of the test. The patient felt only mild dyspnea and tiredness. During 4 minutes 
of restitution period there was complete recovery of ST-segment
• Conclusion: test is positive.
Exercise treadmill test: Maximum 
Exertion
• ST depression on V4-V6 and on lead II,III and aVF
Exercise treadmill test: Recovery phase
• Observed changes were reversed
Coronary angiography
• The right type of coronary blood supply. 
Significant coronary tortuosity. Left 
coronary artery - prolonged 
myocardium bridging in the middle 
segment of the left anterior descending 
coronary artery with systolic 
compression 90%. 
• The circumflex artery branches  of the 
left coronary artery and right coronary 
artery - with signs of atherosclerotic 
lesions without 
hemodynamic significance
Compression of coronary artery in systole
systole diastole


Clinical Diagnosis
• Main disease: Myocardial bridge of LAD with systolic 
compression 90%. Coronary stenting of LAD. HF 0-1. 
High risk.
• Concomitant diseases: Arterial hypertension II st 3degree. 
Hypertensive heart.
Treatment
• Pharmacologic treatment before stenting:
ekvartor 20/10mg every evening,
physiotens 0.2mg daily,
amlodipine 5mg every evening,
korvaltab 1tab 2 times daily,
mildronat 10%,
cardiarginin 5.0 plus physiotens
• Surgical treatment:  Coronary stenting
Treadmill after stenting(early phase)
Treadmill after stenting(Maximum exertion)
Treadmill test was negative. No complaint of angina
Coronary Angiography after Stenting
• Blood pressure was unstable after stent
Treatment after stent
 ecvator 20/10mg in the morning
 physiotens 0.4mg in the evening
 Amlodipine 5mg in the evening
 Krestor 40mg in the evening
 Plaviks 75mg
• Drug recommendation after stenting
ecvator 20/10mg in the morning,
bisoprolol 5mg daily,
roksera 20mg daily,
physiotens 0.4mg in the evening
Amlodipine 5mg in the evening
Krestor 40mg in the evening
Plaviks 75mg
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